145 related articles for article (PubMed ID: 17336621)
21. Ability to develop rhus allergic contact dermatitis in a patient with psoriasis receiving etanercept.
Myers W; Newman M; Katz B; Gottlieb AB
J Am Acad Dermatol; 2006 Nov; 55(5 Suppl):S127-8. PubMed ID: 17052536
[No Abstract] [Full Text] [Related]
22. Lumboperitoneal shunting of cerebrospinal fluid versus anti-tumor necrosis factor treatment of cauda equina syndrome in ankylosing spondylitis: comment on the article by Cornec et al.
Ea HK; Lot G; Bardin T
Arthritis Rheum; 2010 May; 62(5):1559-60; author reply 1560-1. PubMed ID: 20178129
[No Abstract] [Full Text] [Related]
23. Central nervous system Aspergillus fumigatus presenting as cranial nerve palsy in a patient with ankylosing spondylitis on anti-TNF therapy.
Slusher JR; Maldonado ME; Mousavi F; Lozada CJ
Rheumatology (Oxford); 2008 May; 47(5):739-40. PubMed ID: 18381385
[No Abstract] [Full Text] [Related]
24. Severe refractory rheumatoid arthritis successfully treated with combination rituximab and anti-tumor necrosis factor-alpha-blocking agents.
Koumakis E; Wipff J; Avouac J; Kahan A; Allanore Y
J Rheumatol; 2009 Sep; 36(9):2125-6. PubMed ID: 19738227
[No Abstract] [Full Text] [Related]
25. Genital HPV lesions and molluscum contagiosum occurring in patients receiving anti-TNF-alpha therapy.
Antoniou C; Kosmadaki MG; Stratigos AJ; Katsambas AD
Dermatology; 2008; 216(4):364-5. PubMed ID: 18285688
[No Abstract] [Full Text] [Related]
26. Live polio vaccine exposure while receiving anti-TNF therapy for reactive arthritis.
Badsha H; Daher M; Edwards CJ
Int J Rheum Dis; 2010 May; 13(2):184-6. PubMed ID: 20536606
[TBL] [Abstract][Full Text] [Related]
27. Use of tumor necrosis factor-alpha inhibitors in patients with chronic hepatitis B infection.
Carroll MB; Bond MI
Semin Arthritis Rheum; 2008 Dec; 38(3):208-17. PubMed ID: 18221983
[TBL] [Abstract][Full Text] [Related]
28. Successful treatment with etanercept of von Zumbusch pustular psoriasis in a patient with human immunodeficiency virus.
Mikhail M; Weinberg JM; Smith BL
Arch Dermatol; 2008 Apr; 144(4):453-6. PubMed ID: 18427038
[No Abstract] [Full Text] [Related]
29. Anti-tumour necrosis factor treatment in patients with refractory systemic vasculitis associated with rheumatoid arthritis.
Puéchal X; Miceli-Richard C; Mejjad O; Lafforgue P; Marcelli C; Solau-Gervais E; Steinfeld S; Villoutreix C; Trèves R; Mariette X; Guillevin L;
Ann Rheum Dis; 2008 Jun; 67(6):880-4. PubMed ID: 18037625
[TBL] [Abstract][Full Text] [Related]
30. Etanercept for the treatment of hidradenitis suppurativa.
Sotiriou E; Apalla Z; Ioannidos D
Acta Derm Venereol; 2009; 89(1):82-3. PubMed ID: 19197548
[No Abstract] [Full Text] [Related]
31. Recalcitrant lithium-induced psoriasis in a suicidal patient alleviated by tumour necrosis factor-alpha inhibition.
Wachter T; Murach WM; Bröcker EB; Schön MP
Br J Dermatol; 2007 Sep; 157(3):627-9. PubMed ID: 17596151
[No Abstract] [Full Text] [Related]
32. Pretreatment tumour necrosis factor-alpha secretions from peripheral blood mononuclear cells of psoriatic patients do not correlate with rapid clinical response: urgent need for prognostic parameters.
Lan CC; Wu CS; Chen GS
J Eur Acad Dermatol Venereol; 2008 Mar; 22(3):398-9. PubMed ID: 18269626
[No Abstract] [Full Text] [Related]
33. Acute myelogenous leukemia in a patient receiving etanercept for psoriasis.
Bachmeyer C; Thiolière B; Khosrotehrani K; Cattan E
J Am Acad Dermatol; 2007 Jan; 56(1):169-70. PubMed ID: 17190640
[No Abstract] [Full Text] [Related]
34. [Efficacy of tumor necrosis factor-alpha blockade for severe sciatica?].
Genevay S; Guerne PA; Gabay C
Rev Med Suisse Romande; 2004 Sep; 124(9):543-5. PubMed ID: 15552747
[TBL] [Abstract][Full Text] [Related]
35. Palmoplantar pustulosis with arthro-osteitis: successful treatment with etanercept and acitretin.
Antoniou C; Nicolaidou E; Moustou AE; Stratigos A; Katsambas A
J Eur Acad Dermatol Venereol; 2009 Jul; 23(7):854-5. PubMed ID: 19646137
[No Abstract] [Full Text] [Related]
36. Acute graft-versus-host disease after liver transplant: novel use of etanercept and the role of tumor necrosis factor alpha inhibitors.
Thin L; Macquillan G; Adams L; Garas G; Seow C; Cannell P; Augustson B; Mitchell A; Delriveire L; Jeffrey G
Liver Transpl; 2009 Apr; 15(4):421-6. PubMed ID: 19326415
[TBL] [Abstract][Full Text] [Related]
37. Urticaria pigmentosa after treatment with TNF antagonists: a case report.
Leloup P; Daviet V; Chiffoleau A; Dréno B
Arch Dermatol; 2011 Dec; 147(12):1459-60. PubMed ID: 22184778
[No Abstract] [Full Text] [Related]
38. The use of etanercept and other tumor necrosis factor-alpha blockers in infertility: it's time to get serious.
Wallace DJ
J Rheumatol; 2003 Sep; 30(9):1897-9. PubMed ID: 12966586
[No Abstract] [Full Text] [Related]
39. Maintaining and optimising anti-TNF therapy.
Somerville M
Musculoskeletal Care; 2007 Dec; 5 Suppl 1():1-17. PubMed ID: 18050263
[No Abstract] [Full Text] [Related]
40. Determining which patients with myelodysplastic syndrome will respond to immunosuppressive treatment.
Barrett J; Sloand E; Young N
Haematologica; 2006 May; 91(5):583-4. PubMed ID: 16670061
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
